FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021702941> ?p ?o ?g. }

• W2021702941 endingPage "705" @default.
• W2021702941 startingPage "700" @default.
• W2021702941 abstract "To investigate the clinical safety and efficacy of two dosages of tolterodine in older patients with symptoms attributable to overactive bladder.Randomized, double-blind, placebo-controlled, parallel-group, multinational, phase III study.Incontinence, older care, urological, and urogynecological clinics in the United Kingdom, France, and the Republic of Ireland.One hundred and seventy-seven older patients (age > or =65 years) with symptoms of urinary urgency, increased frequency of micturition (> or =8 micturitions/24 hours), and/or urge incontinence (> or =1 episode/24 hours).Tolterodine 1 mg or 2 mg twice daily (bid), or placebo, for 4 weeks.Safety and tolerability were evaluated through spontaneously reported adverse events, electrocardiogram, and blood pressure measurements. Efficacy was assessed using micturition diary variables: mean change from baseline in frequency of micturition and number of incontinence episodes/24 hours.The mean age of the patient population was 75 years. Overall, > or =87% of patients completed the study. Neither dosage of tolterodine was associated with serious drug-related adverse events during the study. No cardiac arrythmogenic events were noted. Dry mouth (mild to moderate intensity) was the most common adverse event in both the placebo and tolterodine treatment groups. Three percent of patients in the tolterodine 2 mg bid group discontinued treatment because of dry mouth, compared with 2% of placebo-treated patients. Compared with placebo, statistically significant decreases in micturition frequency were apparent in both tolterodine treatment groups. Furthermore, patients treated with tolterodine 2 mg bid had statistically significant decreases in urge incontinence episodes/24 hours and increases in volume voided per micturition compared with placebo.Tolterodine (taken for 4 weeks) is safe and shows efficacy, particularly at a dosage of 2 mg bid, in the treatment of older patients with urinary symptoms attributable to overactive bladder." @default.
• W2021702941 created "2016-06-24" @default.
• W2021702941 creator A5003815090 @default.
• W2021702941 creator A5014700982 @default.
• W2021702941 creator A5083358651 @default.
• W2021702941 date "2001-06-01" @default.
• W2021702941 modified "2023-09-25" @default.
• W2021702941 title "Tolterodine: A Safe and Effective Treatment for Older Patients with Overactive Bladder" @default.
• W2021702941 cites W1410775549 @default.
• W2021702941 cites W1600603445 @default.
• W2021702941 cites W1977586210 @default.
• W2021702941 cites W1989882486 @default.
• W2021702941 cites W2005791359 @default.
• W2021702941 cites W2008079238 @default.
• W2021702941 cites W2021433768 @default.
• W2021702941 cites W2024975356 @default.
• W2021702941 cites W2030052255 @default.
• W2021702941 cites W2036256104 @default.
• W2021702941 cites W2039546045 @default.
• W2021702941 cites W2039602892 @default.
• W2021702941 cites W2042053041 @default.
• W2021702941 cites W2046456635 @default.
• W2021702941 cites W2059240022 @default.
• W2021702941 cites W2064430566 @default.
• W2021702941 cites W2068505222 @default.
• W2021702941 cites W2072187682 @default.
• W2021702941 cites W2073149905 @default.
• W2021702941 cites W2074323366 @default.
• W2021702941 cites W2083510953 @default.
• W2021702941 cites W2088679190 @default.
• W2021702941 cites W2097501252 @default.
• W2021702941 cites W2109298103 @default.
• W2021702941 cites W2414406991 @default.
• W2021702941 cites W4256614772 @default.
• W2021702941 doi "https://doi.org/10.1046/j.1532-5415.2001.49144.x" @default.
• W2021702941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11454106" @default.
• W2021702941 hasPublicationYear "2001" @default.
• W2021702941 type Work @default.
• W2021702941 sameAs 2021702941 @default.
• W2021702941 citedByCount "133" @default.
• W2021702941 countsByYear W20217029412012 @default.
• W2021702941 countsByYear W20217029412013 @default.
• W2021702941 countsByYear W20217029412014 @default.
• W2021702941 countsByYear W20217029412015 @default.
• W2021702941 countsByYear W20217029412016 @default.
• W2021702941 countsByYear W20217029412017 @default.
• W2021702941 countsByYear W20217029412018 @default.
• W2021702941 countsByYear W20217029412020 @default.
• W2021702941 countsByYear W20217029412021 @default.
• W2021702941 countsByYear W20217029412023 @default.
• W2021702941 crossrefType "journal-article" @default.
• W2021702941 hasAuthorship W2021702941A5003815090 @default.
• W2021702941 hasAuthorship W2021702941A5014700982 @default.
• W2021702941 hasAuthorship W2021702941A5083358651 @default.
• W2021702941 hasConcept C126322002 @default.
• W2021702941 hasConcept C126894567 @default.
• W2021702941 hasConcept C142724271 @default.
• W2021702941 hasConcept C175768497 @default.
• W2021702941 hasConcept C197934379 @default.
• W2021702941 hasConcept C204787440 @default.
• W2021702941 hasConcept C27081682 @default.
• W2021702941 hasConcept C2778375690 @default.
• W2021702941 hasConcept C2778531004 @default.
• W2021702941 hasConcept C2778941218 @default.
• W2021702941 hasConcept C2781020410 @default.
• W2021702941 hasConcept C2908647359 @default.
• W2021702941 hasConcept C42219234 @default.
• W2021702941 hasConcept C71924100 @default.
• W2021702941 hasConcept C77411442 @default.
• W2021702941 hasConcept C99454951 @default.
• W2021702941 hasConceptScore W2021702941C126322002 @default.
• W2021702941 hasConceptScore W2021702941C126894567 @default.
• W2021702941 hasConceptScore W2021702941C142724271 @default.
• W2021702941 hasConceptScore W2021702941C175768497 @default.
• W2021702941 hasConceptScore W2021702941C197934379 @default.
• W2021702941 hasConceptScore W2021702941C204787440 @default.
• W2021702941 hasConceptScore W2021702941C27081682 @default.
• W2021702941 hasConceptScore W2021702941C2778375690 @default.
• W2021702941 hasConceptScore W2021702941C2778531004 @default.
• W2021702941 hasConceptScore W2021702941C2778941218 @default.
• W2021702941 hasConceptScore W2021702941C2781020410 @default.
• W2021702941 hasConceptScore W2021702941C2908647359 @default.
• W2021702941 hasConceptScore W2021702941C42219234 @default.
• W2021702941 hasConceptScore W2021702941C71924100 @default.
• W2021702941 hasConceptScore W2021702941C77411442 @default.
• W2021702941 hasConceptScore W2021702941C99454951 @default.
• W2021702941 hasIssue "6" @default.
• W2021702941 hasLocation W20217029411 @default.
• W2021702941 hasLocation W20217029412 @default.
• W2021702941 hasOpenAccess W2021702941 @default.
• W2021702941 hasPrimaryLocation W20217029411 @default.
• W2021702941 hasRelatedWork W2005182544 @default.
• W2021702941 hasRelatedWork W2006171475 @default.
• W2021702941 hasRelatedWork W2032792883 @default.
• W2021702941 hasRelatedWork W2068543068 @default.
• W2021702941 hasRelatedWork W2071699168 @default.
• W2021702941 hasRelatedWork W2082897746 @default.
• W2021702941 hasRelatedWork W2088252790 @default.

• next